Biowaiver for Lower Strength [Regulatives / Guidelines]

posted by wienui  – Germany/Oman, 2020-11-24 10:42 (672 d 20:54 ago) – Posting: # 22081
Views: 1,361

(edited by wienui on 2020-11-24 11:09)

Hi Vandee & Ohlbe,

As Ohlbe said, according to EMA for an additional strength biowaiver, the Amount of API(s) must be < 5% of tablet (capsule) core weight for both strengths, the BE strength and the biowaiver one.
Moreover, the Amounts of excipients are the same per strength or Only the amount of a filler is changed to account for changes in API weight.

The FDA doesn't consider this 5% rule and the requirements for an additional strength biowaiver are as following:Both EMA & FDA are asking for the Similarity of dissolution characteristics of the biowaiver strength to the strength for which bioequivalence has been demonstrated in vivo.

I hope this could help.


Complete thread:

UA Flag
 Admin contact
22,391 posts in 4,685 threads, 1,595 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Wednesday 08:36 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz